Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Total Liabilities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Total Liabilities for 11 consecutive years, with $37.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities changed N/A to $37.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $37.3 million for FY2025, N/A changed from the prior year.
  • Total Liabilities for Q4 2025 was $37.3 million at Crescent Biopharma, up from $21.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $37.3 million in Q4 2025, with the low at $2.6 million in Q1 2025.
  • Average Total Liabilities over 5 years is $11.0 million, with a median of $8.9 million recorded in 2022.
  • Peak annual rise in Total Liabilities hit 400.43% in 2025, while the deepest fall reached 50.57% in 2025.
  • Over 5 years, Total Liabilities stood at $12.7 million in 2021, then tumbled by 30.31% to $8.9 million in 2022, then fell by 22.28% to $6.9 million in 2023, then crashed by 37.38% to $4.3 million in 2024, then soared by 762.62% to $37.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $37.3 million, $21.6 million, and $18.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.